Key terms
About PTGX
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PTGX news
Mar 18
7:10am ET
Protagonist closes rusfertide license, collaboration agreement with Takeda
Mar 11
12:05pm ET
Buy Rating Affirmed for Protagonist Therapeutics on Strong Phase 2b Results and Strategic Phase 3 Dosing of JNJ-2113
Mar 11
8:41am ET
Protagonist Therapeutics announces presentation of data on JNJ-2113
Mar 11
12:25am ET
Strong Buy Rating for Protagonist Therapeutics on JNJ-2113’s Promising Psoriasis Treatment Efficacy and Financial Outlook
Feb 29
1:02am ET
New Debt & Financing Risk for Protagonist Therapeutics Inc – What’s the Latest?
Feb 28
8:40am ET
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Progyny (PGNY) and Protagonist Therapeutics (PTGX)
Feb 28
7:10am ET
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Protagonist Therapeutics (PTGX) and Viridian Therapeutics (VRDN)
Feb 28
7:06am ET
Buy Rating Affirmed for Protagonist Therapeutics on Strong Pipeline and Strategic Partnerships
Feb 28
12:40am ET
Analysts Are Bullish on These Healthcare Stocks: Gritstone Oncology (GRTS), Protagonist Therapeutics (PTGX)
Feb 09
10:16am ET
Protagonist Therapeutics Earns ‘Buy’ Rating: Promising Clinical Advances and Strategic Partnerships
Feb 01
11:49pm ET
3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts
Feb 01
8:19pm ET
Buy Rating on Protagonist Therapeutics: Strategic Takeda Partnership and Rusfertide’s Market Potential
Feb 01
12:00pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 01
6:47am ET
Buy Rating Affirmed for Protagonist Therapeutics Following Strategic Takeda Collaboration and Promising Drug Pipeline
Feb 01
6:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF) and Protagonist Therapeutics (PTGX)
Jan 31
6:41pm ET
Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide
Jan 29
3:20am ET
3 Best Stocks to Buy Now, 1/29/2024, According to Top Analysts
Jan 26
12:25am ET
Buy Rating on Protagonist Therapeutics: Anticipating Rusfertide Success and Strategic Acquisition Upside
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
10:44am ET
Capital One says buy these six biotech stocks for 2024
Jan 25
9:03am ET
Capital One reveals top six biotech picks for 2024
Jan 07
5:39am ET
BTIG Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
Jan 02
9:46am ET
BTIG Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)
Dec 31
5:23am ET
BTIG Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)
No recent news articles are available for PTGX
No recent press releases are available for PTGX
PTGX Financials
Key terms
Ad Feedback
PTGX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PTGX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range